DOSAGE INDEX / SINGLE
HGH 191AA
Research, reported schedules and supply planning.
Separate HGH replacement from enhancement claims using original body-composition and athlete trials, official labeling and diagnostic guidance.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 150–500 micrograms per day in the overview; separate examples use 1–2 mg
- Frequency
- Once daily
- Cycle / observation period
- 8–12 weeks; source also mentions 16 weeks
- Route / research model
- Subcutaneous
The overview starts at 150 micrograms while its starting-dose narrative uses 200 micrograms. This is not a substitute for an indication-specific somatropin label.
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 10 IU | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- GENOTROPIN has defined pediatric indications and an adult indication for growth-hormone replacement in patients with growth-hormone deficiency. Its label describes diagnostic requirements and exceptions rather than treating a wish for improved body composition as a diagnosis. [1]
- Papadakis and colleagues studied 52 healthy men older than 69 with low baseline IGF-1 and preserved function. Over six months, GH increased lean mass and reduced fat mass compared with placebo, but did not significantly improve measured grip strength, knee strength or systemic endurance. Cognitive results differed by test. The GH group had more reported side-effect events and more dose reductions. [3]
- A 2010 trial enrolled 96 recreational athletes and evaluated eight weeks of treatment, with later follow-up. GH reduced fat and increased lean mass, with extracellular water contributing to the lean-mass change. Sprint capacity improved, while other tested performance measures did not significantly improve. The sprint effect was not maintained six weeks after treatment stopped. Men receiving GH with testosterone showed a larger sprint effect; that combination result should remain separate from GH alone. The authors considered the study too small to establish safety. [4]
- The GENOTROPIN label includes contraindications involving active malignancy and certain acute critical illnesses, among others. Warnings include glucose intolerance, intracranial hypertension and fluid retention. These are selected examples, not a complete prescribing checklist. [1]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 12 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- GENOTROPIN prescribing information
- Hypopituitarism guideline, recommendations 1.9 to 1.11
- 1996 original randomized trial
- Meinhardt and colleagues, original trial
- FDA Genotropin Prescribing InformationRegulatory / product information · Listed in reference bibliography.
- Medsafe NZ Data Sheet (Omnitrope)Further reading · Listed in reference bibliography.
- Hadzovic et al., Bosn. J. Basic Med. Sci. 2004Further reading · Listed in reference bibliography.
- Rudman et al., N. Engl. J. Med. 1990Further reading · Listed in reference bibliography.
- Liu et al., Ann. Intern. Med. 2008Further reading · Listed in reference bibliography.
- CDC Vaccine Administration GuidelinesGeneral guidance · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.